Lasa Supergenerics Expands Albendazole USP Manufacturing Capacity by 20%

Lasa Supergenerics Ltd, a leading innovator in the animal and human healthcare value chain, has successfully expanded its manufacturing capacity for Albendazole USP by 20%. This was achieved through strategic debottlenecking of existing infrastructure and the installation of new machinery at its manufacturing facility. The expansion strengthens Lasa’s ability to meet increasing demand for Albendazole across domestic and international markets, improves product efficiency, and reduces lead time. The total capacity is anticipated to represent a growth of 20%, supported by a capital investment (CAPEX) of nearly Rs. 100.00 Lakhs. Dr. Omkar Herlekar, Chairman and Managing Director of the Company, expressed his delight about the expansion, reinforcing Lasa’s commitment to supporting customers and fortifying its role as a reliable APl supplier in the pharmaceutical industry.